Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by dynamic left ventricular outflow tract ( LVOT ) obstruction, which can contribute to symptoms and impaired functional capacity. The ability to achieve sustained reductions in LVOT gradients while improving functional status remains an important therapeutic goal. 1,2 Clinical evidence with mavacamten demonstrates that meaningful benefits can emerge early, with improvements reported as early as Weeks 4–6 and sustained with longer-term treatment.

In EXPLORER-HCM , mavacamten was associated with a significant reduction in post-exercise LVOT gradient, improvement in NYHA functional class, and increased peak oxygen consumption (pVO₂), reflecting improved exercise capacity. 2,3 Long-term data further demonstrate persistent reductions in resting and Valsalva LVOT gradients, with continued relief of obstruction through Week 128.…